SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Want to cut your energy bills? Here’s how five experts are doing it 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at 10:40 a.m. E.T. on Tuesday, March 7, 2017 in Boston.
A live webcast of the presentation will be available by visiting the Investors and Media section of Jounce’s website at http://ir.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 1/2 trial. For more information, please visit http://jouncetx.com/.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
